 AVEO Pharmaceuticals Incs NASDAQ: AVEO brief positive news of getting FDA approval for Tivozanib in relapsed kidney cancer this month was upset after its partner CANbridge Life Sciences voluntarily terminated the collaboration agreement. The company said it would regain its rights to the investigational cancer med AV-203 outside North America from early September. 